Remus Pharmaceuticals Profit & Loss Annual

BSE: - | NSE: REMUS | ISIN: INE0O5T01011 | Sector: -

898.60 -26.90 (-2.91%)Updated : 09 Jul 2025

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Total Operating Expense	185.59	34.96	20.80	17.83
Other Net	0.89	0.45	0.18	0.57
Diluted Weighted Average Shares	0.57	0.82	1.18	1.18
Gain( Loss)on Saleof Assets	1.51	-	-	-
Depreciation/ Amortization	0.90	0.48	0.15	0.18
Operating Income	26.91	10.07	3.92	0.59
Net Income	21.54	8.50	3.39	1.03
Income Availableto Com Excl Extra Ord	21.54	8.50	3.39	1.03
Other Operating Expenses Total	0.02	0.00	0.00	0.01
Net Income Before Taxes	31.83	11.41	4.55	1.36
Minority Interest	-4.44	-	-	-
Net Income After Taxes	25.98	8.50	3.39	1.03
Income Availableto Com Incl Extra Ord	21.54	8.50	3.39	1.03
Costof Revenue Total	164.33	21.44	12.27	11.49
Gross Profit	48.17	23.59	12.45	6.92
Interest Inc( Exp) Net- Non- Op Total	2.52	0.89	0.45	0.20
Diluted Net Income	21.54	8.50	3.39	1.03
DPS- Common Stock Primary Issue	1.50	0.25	0.00	0.00
Provisionfor Income Taxes	5.85	2.91	1.16	0.33
period Type	-	-	-	-
Net Income Before Extra Items	21.54	8.50	3.39	1.03
Total Revenue	212.50	45.03	24.72	18.42
period Length	12.00	12.00	12.00	12.00
Revenue	212.50	45.03	24.72	18.42
Selling/ General/ Admin Expenses Total	20.35	13.02	8.37	6.15
Diluted Normalized EPS	35.82	10.42	2.87	0.87
Diluted EPS Excluding Extra Ord Items	38.00	10.41	2.87	0.87
Unusual Expense( Income)	-	0.02	0.00	0.00